A Trial Investigating the Pharmacodynamic Properties of NN1218 in Subjects With Type 1 Diabetes

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

June 11, 2012

Primary Completion Date

September 7, 2012

Study Completion Date

September 7, 2012

Conditions
DiabetesDiabetes Mellitus, Type 1
Interventions
DRUG

Faster-acting insulin aspart

A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.

DRUG

insulin aspart

A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.

Trial Locations (1)

41460

Novo Nordisk Investigational Site, Neuss

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY